Drugs / AMG 211
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02760199 | Aug 2016 → May 2017 | digestive system cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1 | NCT02291614 | Nov 2014 → Nov 2017 | adenocarcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 211 | “AMG 211 is a bispecific single-chain antibody construct of the bispecific T-cell engager (BiTE®) class that targets human carcinoembryonic antigen (CEA, CD66e) on (tumor) cells...” NCT02760199 ↗ |
| Modality | Protein / enzyme biologic | “AMG 211 is a bispecific single-chain antibody construct of the bispecific T-cell engager (BiTE®) class” NCT02760199 ↗ |
| Route | Intravenous | “continuous intravenous infusion” NCT02291614 ↗ |